drugset / Trial / NCT03085056

Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

NCT03085056

Phase 0 Active not recruiting 13 enrolled Memorial Sloan Kettering Cancer Center Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.

Timeline

Start
2017-03-15
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 80 mg/m2
Subject Trametinib Small molecule 2 mg Oral